FDA Panel Backs Proposed Tofacitinib Dosing for Ulcerative Colitis FDA Panel Backs Proposed Tofacitinib Dosing for Ulcerative Colitis
Pfizer scored a win in its efforts to move forward a delayed application for new use of its rheumatoid arthritis drug for treating chronic inflammation of the colon.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news
More News: Arthritis | Gastroenterology | Health | Inflammatory Bowel Disease | Pfizer | Rheumatoid Arthritis | Rheumatology | Ulcerative Colitis